fluconazole has been researched along with Esophageal Diseases in 50 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Esophageal Diseases: Pathological processes in the ESOPHAGUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy and safety of oral posaconazole for human immunodeficiency virus (HIV)-infected subjects with oropharyngeal candidiasis (OPC) and/or esophageal candidiasis (EC) who were clinically refractory to treatment with oral fluconazole or itraconazole." | 9.12 | Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. ( Anstead, GM; Boparai, N; Graybill, JR; Hare, R; Isaacs, R; Reynes, J; Skiest, DJ; Vazquez, JA; Ward, D, 2007) |
| " This randomized, double-blind, double-dummy study compared the efficacy and safety of intravenous anidulafungin to that of oral fluconazole in 601 patients with endoscopically and microbiologically documented esophageal candidiasis." | 9.11 | A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. ( Goldstein, BP; Henkel, T; Krause, DS; Simjee, AE; van Rensburg, C; Viljoen, J; Walsh, TJ; Wible, M, 2004) |
| "A total of 245 patients (age, > or =18 years) with a prior diagnosis of acquired immunodeficiency syndrome/human immunodeficiency virus (HIV) infection and esophageal candidiasis, confirmed by endoscopy and culture, were randomized to receive micafungin (50, 100, or 150 mg per day) or fluconazole (200 mg per day)." | 9.11 | A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. ( Baraldi, E; de Wet, N; Della Negra, M; Diekmann-Berndt, H; Krantz, EF; Llanos-Cuentas, A; Suleiman, J, 2004) |
| "Intravenous micafungin (150 mg daily) is well tolerated and as efficacious as intravenous fluconazole (200 mg daily) in the primary treatment of oesophageal candidiasis, achieving high rates of clinical and endoscopic cure." | 9.11 | A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. ( Bester, AJ; Buell, D; de Wet, NT; Filho, F; Fisco, C; Lau, W; Llanos, EA; Suleiman, JM; Ticona, E; Viljoen, JJ, 2005) |
| "Caspofungin is a new echinocandin drug with comparable in vitro activity against azole-susceptible and -resistant isolates of that could provide a less toxic alternative to amphotericin B for the management of esophageal candidiasis with clinical or laboratory evidence of decreased susceptibility to fluconazole." | 9.10 | Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. ( Bartizal, K; DiNubile, MJ; Hicks, PS; Kartsonis, N; Ryan, D; Sable, CA, 2002) |
| "The efficacy, safety, and tolerability of voriconazole and fluconazole were compared in 391 immunocompromised patients with mycology- and biopsy-proven esophageal candidiasis." | 9.09 | A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. ( Aguirrebengoa, K; Ally, R; Carosi, G; Dupont, B; Hodges, M; Kreisel, W; Romero, AJ; Schürmann, D; Troke, P, 2001) |
| "This multicenter, randomized, double-blind study compared the efficacy and safety of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis." | 9.08 | A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. ( Darouiche, RO; Laine, L; Mallegol, I; Moskovitz, BL; Wilcox, CM; Wu, J, 1997) |
| "Symptoms resolved in 100% of patients with AIDS and oesophageal candidiasis receiving an oral suspension of fluconazole, and 90% of patients had symptom resolution within 2 weeks." | 9.08 | Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. ( Laine, L; Rabeneck, L, 1995) |
| "In order to evaluate the efficacy of 200 mg single weekly dose of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS, 18 patients who had an endoscopic confirmation of cure after an esophageal candidiasis, were studied." | 9.07 | [Secondary prevention of esophageal candidiasis with fluconazole in acquired immunodeficiency syndrome]. ( García Puig, J; Gil, A; Khamashta, M; Lavilla Uriol, P; López Dupla, M; Ortiz Vázquez, J; Pintado, V; Valencia, E, 1992) |
| "A prospective, multicenter, open study of fluconazole prophylaxis was performed in AIDS patients to evaluate the efficacy and toxicity of the drug in preventing relapses of esophageal candidiasis." | 9.07 | Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study. ( Agresti, MG; Bellocco, R; Caputo, RM; Carosi, GP; Chiodo, F; de Bernardis, F; Giannini, V; Milazzo, F; Minoli, L; Mondello, F, 1994) |
| "We studied the prevalence of fluconazole resistance in esophageal candidiasis." | 7.80 | Is empiric therapy with fluconazole appropriate for esophageal candidiasis? ( Chacko, A; Dutta, AK; Esakimuthu, S; Sahni, RD; Sajith, KG, 2014) |
| " We studied the activity of PLD-118 in escalating dosages against experimental oropharyngeal and esophageal candidiasis (OPEC) caused by fluconazole (FLC)-resistant Candida albicans in immunocompromised rabbits." | 7.72 | Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. ( Bacher, J; Groll, AH; Kelaher, AM; Mickiene, D; Petraitiene, R; Petraitis, V; Sarafandi, AA; Sein, T; Walsh, TJ, 2004) |
| " We studied the antifungal efficacy, the concentrations in saliva and tissue, and the safety of VER-002 at escalating dosages against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant Candida albicans in immunocompromised rabbits." | 7.71 | Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. ( Bacher, J; Francesconi, A; Groll, AH; Lyman, CA; Petraitiene, R; Petraitis, V; Piscitelli, SC; Schaufele, RL; Sein, T; Walsh, TJ, 2001) |
| "In our study 77 AIDS patients suffering from oral and/or esophageal candidiasis were evaluated: 38 received fluconazole, 39 ketoconazole." | 7.68 | Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients. ( Ancarani, F; Arzeni, D; Barchiesi, F; Branchesi, P; Crescenzi, G; Giacometti, A; Scalise, G, 1992) |
| "Isavuconazole is a novel, broad-spectrum antifungal developed for the treatment of opportunistic fungal infections." | 6.80 | A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. ( Azie, N; Ghannoum, M; Schmitt-Hoffmann, AH; Viljoen, J, 2015) |
| "Fluconazole is a new triazole antifungal agent with good activity against Candida and cryptococcal meningitis." | 6.38 | Fluconazole: a new option in the treatment of Candida mucositis and esophageal candidiasis. ( Garber, GE, 1992) |
| " The concentrations of fluconazole in plasma were maintained above the MICs for FS isolates throughout the dosing interval." | 5.31 | Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. ( Bacher, JD; Gonzalez, CE; Katsov, V; Kligys, K; Lyman, CA; Peter, J; Piscitelli, S; Shetti, D; Torres, R; Walsh, TJ, 2000) |
| "Fluconazole was well tolerated in all the patients." | 5.28 | [Treatment of esophageal candidiasis with fluconazole in acquired immunodeficiency syndrome. Comparative study of 2 therapeutic schemes]. ( García Puig, J; Gil, A; Khamashta, M; Lavilla, P; López Dupla, M; Ortiz-Vázquez, J; Pintado, V; Valencia, E, 1992) |
| "We evaluated the efficacy and safety of oral posaconazole for human immunodeficiency virus (HIV)-infected subjects with oropharyngeal candidiasis (OPC) and/or esophageal candidiasis (EC) who were clinically refractory to treatment with oral fluconazole or itraconazole." | 5.12 | Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. ( Anstead, GM; Boparai, N; Graybill, JR; Hare, R; Isaacs, R; Reynes, J; Skiest, DJ; Vazquez, JA; Ward, D, 2007) |
| " This randomized, double-blind, double-dummy study compared the efficacy and safety of intravenous anidulafungin to that of oral fluconazole in 601 patients with endoscopically and microbiologically documented esophageal candidiasis." | 5.11 | A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. ( Goldstein, BP; Henkel, T; Krause, DS; Simjee, AE; van Rensburg, C; Viljoen, J; Walsh, TJ; Wible, M, 2004) |
| "A total of 245 patients (age, > or =18 years) with a prior diagnosis of acquired immunodeficiency syndrome/human immunodeficiency virus (HIV) infection and esophageal candidiasis, confirmed by endoscopy and culture, were randomized to receive micafungin (50, 100, or 150 mg per day) or fluconazole (200 mg per day)." | 5.11 | A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. ( Baraldi, E; de Wet, N; Della Negra, M; Diekmann-Berndt, H; Krantz, EF; Llanos-Cuentas, A; Suleiman, J, 2004) |
| "Intravenous micafungin (150 mg daily) is well tolerated and as efficacious as intravenous fluconazole (200 mg daily) in the primary treatment of oesophageal candidiasis, achieving high rates of clinical and endoscopic cure." | 5.11 | A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. ( Bester, AJ; Buell, D; de Wet, NT; Filho, F; Fisco, C; Lau, W; Llanos, EA; Suleiman, JM; Ticona, E; Viljoen, JJ, 2005) |
| "Caspofungin is a new echinocandin drug with comparable in vitro activity against azole-susceptible and -resistant isolates of that could provide a less toxic alternative to amphotericin B for the management of esophageal candidiasis with clinical or laboratory evidence of decreased susceptibility to fluconazole." | 5.10 | Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. ( Bartizal, K; DiNubile, MJ; Hicks, PS; Kartsonis, N; Ryan, D; Sable, CA, 2002) |
| "The efficacy, safety, and tolerability of voriconazole and fluconazole were compared in 391 immunocompromised patients with mycology- and biopsy-proven esophageal candidiasis." | 5.09 | A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. ( Aguirrebengoa, K; Ally, R; Carosi, G; Dupont, B; Hodges, M; Kreisel, W; Romero, AJ; Schürmann, D; Troke, P, 2001) |
| "This multicenter, randomized, double-blind study compared the efficacy and safety of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis." | 5.08 | A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. ( Darouiche, RO; Laine, L; Mallegol, I; Moskovitz, BL; Wilcox, CM; Wu, J, 1997) |
| "Symptoms resolved in 100% of patients with AIDS and oesophageal candidiasis receiving an oral suspension of fluconazole, and 90% of patients had symptom resolution within 2 weeks." | 5.08 | Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS. ( Laine, L; Rabeneck, L, 1995) |
| "A prospective, multicenter, open study of fluconazole prophylaxis was performed in AIDS patients to evaluate the efficacy and toxicity of the drug in preventing relapses of esophageal candidiasis." | 5.07 | Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study. ( Agresti, MG; Bellocco, R; Caputo, RM; Carosi, GP; Chiodo, F; de Bernardis, F; Giannini, V; Milazzo, F; Minoli, L; Mondello, F, 1994) |
| "In order to evaluate the efficacy of 200 mg single weekly dose of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS, 18 patients who had an endoscopic confirmation of cure after an esophageal candidiasis, were studied." | 5.07 | [Secondary prevention of esophageal candidiasis with fluconazole in acquired immunodeficiency syndrome]. ( García Puig, J; Gil, A; Khamashta, M; Lavilla Uriol, P; López Dupla, M; Ortiz Vázquez, J; Pintado, V; Valencia, E, 1992) |
| "We studied the prevalence of fluconazole resistance in esophageal candidiasis." | 3.80 | Is empiric therapy with fluconazole appropriate for esophageal candidiasis? ( Chacko, A; Dutta, AK; Esakimuthu, S; Sahni, RD; Sajith, KG, 2014) |
| " We studied the activity of PLD-118 in escalating dosages against experimental oropharyngeal and esophageal candidiasis (OPEC) caused by fluconazole (FLC)-resistant Candida albicans in immunocompromised rabbits." | 3.72 | Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans. ( Bacher, J; Groll, AH; Kelaher, AM; Mickiene, D; Petraitiene, R; Petraitis, V; Sarafandi, AA; Sein, T; Walsh, TJ, 2004) |
| " We studied the antifungal efficacy, the concentrations in saliva and tissue, and the safety of VER-002 at escalating dosages against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant Candida albicans in immunocompromised rabbits." | 3.71 | Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. ( Bacher, J; Francesconi, A; Groll, AH; Lyman, CA; Petraitiene, R; Petraitis, V; Piscitelli, SC; Schaufele, RL; Sein, T; Walsh, TJ, 2001) |
| "In our study 77 AIDS patients suffering from oral and/or esophageal candidiasis were evaluated: 38 received fluconazole, 39 ketoconazole." | 3.68 | Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients. ( Ancarani, F; Arzeni, D; Barchiesi, F; Branchesi, P; Crescenzi, G; Giacometti, A; Scalise, G, 1992) |
| "We describe a patient with the acquired immunodeficiency syndrome who had persistent oral esophageal pseudomembranous candidiasis clinically refractory to nystatin, clotrimazole, and ketoconazole." | 3.68 | Treatment of refractory oral candidiasis with fluconazole. A case report. ( Chafey, S; Franker, C; Hardy, WD; Lucatorto, FM, 1991) |
| "Isavuconazole is a novel, broad-spectrum antifungal developed for the treatment of opportunistic fungal infections." | 2.80 | A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. ( Azie, N; Ghannoum, M; Schmitt-Hoffmann, AH; Viljoen, J, 2015) |
| "Fluconazole has proved to be effective in treating oropharyngeal and esophageal candidiasis in immunocompromised patients." | 2.67 | Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. ( Akalin, HE; Akova, M; Aslan, S; Hayran, M; Kansu, E; Tekuzman, G; Telatar, H; Uzun, O, 1994) |
| "Fluconazole is a new triazole antifungal agent with good activity against Candida and cryptococcal meningitis." | 2.38 | Fluconazole: a new option in the treatment of Candida mucositis and esophageal candidiasis. ( Garber, GE, 1992) |
| "Fluconazole was commenced within 72 h of blood culture positivity in 96." | 1.40 | Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study. ( Chen, SC; Ellis, DH; Marriott, DM; Slavin, M; Sorrell, TC; van Hal, SJ, 2014) |
| "Azoles are safe, effective agents to treat esophageal candidiasis." | 1.33 | Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. ( Cappello, D; Di Mare, M; Fiamingo, P; Gagliano, M; Giuffrida, G; Macarone, M; Severino, V; Sorbello, M; Spataro, M; Veroux, M; Veroux, P; Vizcarra, D, 2006) |
| " The concentrations of fluconazole in plasma were maintained above the MICs for FS isolates throughout the dosing interval." | 1.31 | Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. ( Bacher, JD; Gonzalez, CE; Katsov, V; Kligys, K; Lyman, CA; Peter, J; Piscitelli, S; Shetti, D; Torres, R; Walsh, TJ, 2000) |
| "Recurrences were also responsive to diflucan." | 1.29 | [Use of Diflucan in the treatment of chronic and recurrent candidosis with involvement of the esophagus]. ( Antonov, VV; Barantsevich, EP; Nizamutdinova, AS, 1996) |
| "Almost all patients with acquired immunodeficiency syndrome and successfully treated esophageal candidiasis develop a recurrence, usually within 2-3 months." | 1.29 | The natural history of esophageal candidiasis after successful treatment in patients with AIDS. ( Laine, L, 1994) |
| "Fluconazole was well tolerated in all the patients." | 1.28 | [Treatment of esophageal candidiasis with fluconazole in acquired immunodeficiency syndrome. Comparative study of 2 therapeutic schemes]. ( García Puig, J; Gil, A; Khamashta, M; Lavilla, P; López Dupla, M; Ortiz-Vázquez, J; Pintado, V; Valencia, E, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.00) | 18.7374 |
| 1990's | 28 (56.00) | 18.2507 |
| 2000's | 12 (24.00) | 29.6817 |
| 2010's | 8 (16.00) | 24.3611 |
| 2020's | 1 (2.00) | 2.80 |
| Authors | Studies |
|---|---|
| López Peña, C | 1 |
| Barrientos Delgado, A | 1 |
| Soler Góngora, M | 1 |
| Bamidele, OF | 1 |
| Olokoba, AB | 1 |
| Bojuwoye, MO | 1 |
| Barde, AA | 1 |
| Köklü, S | 1 |
| Köklü, H | 1 |
| Morare, NMT | 1 |
| Rose, DM | 1 |
| Appels, O | 1 |
| Armstrong, MJ | 1 |
| Ahmed, R | 1 |
| Boulton, R | 1 |
| Khan, AT | 1 |
| Dhorajiya, P | 1 |
| Lung, E | 1 |
| Sajith, KG | 1 |
| Dutta, AK | 1 |
| Sahni, RD | 1 |
| Esakimuthu, S | 1 |
| Chacko, A | 1 |
| van Hal, SJ | 1 |
| Chen, SC | 1 |
| Sorrell, TC | 1 |
| Ellis, DH | 1 |
| Slavin, M | 1 |
| Marriott, DM | 1 |
| Viljoen, J | 2 |
| Azie, N | 1 |
| Schmitt-Hoffmann, AH | 1 |
| Ghannoum, M | 1 |
| Kartsonis, N | 1 |
| DiNubile, MJ | 1 |
| Bartizal, K | 1 |
| Hicks, PS | 1 |
| Ryan, D | 1 |
| Sable, CA | 1 |
| Tapia, C | 1 |
| González, P | 1 |
| Pereira, A | 1 |
| Pérez, J | 1 |
| Noriega, LM | 1 |
| Palavecino, E | 1 |
| Petraitis, V | 2 |
| Petraitiene, R | 2 |
| Kelaher, AM | 1 |
| Sarafandi, AA | 1 |
| Sein, T | 2 |
| Mickiene, D | 1 |
| Bacher, J | 2 |
| Groll, AH | 2 |
| Walsh, TJ | 4 |
| Krause, DS | 1 |
| Simjee, AE | 1 |
| van Rensburg, C | 1 |
| Goldstein, BP | 1 |
| Wible, M | 1 |
| Henkel, T | 1 |
| de Wet, N | 1 |
| Llanos-Cuentas, A | 1 |
| Suleiman, J | 1 |
| Baraldi, E | 1 |
| Krantz, EF | 1 |
| Della Negra, M | 1 |
| Diekmann-Berndt, H | 1 |
| Kamai, Y | 1 |
| Kakuta, M | 1 |
| Shibayama, T | 1 |
| Fukuoka, T | 1 |
| Kuwahara, S | 1 |
| de Wet, NT | 1 |
| Bester, AJ | 1 |
| Viljoen, JJ | 1 |
| Filho, F | 1 |
| Suleiman, JM | 1 |
| Ticona, E | 1 |
| Llanos, EA | 1 |
| Fisco, C | 1 |
| Lau, W | 1 |
| Buell, D | 1 |
| Veroux, M | 1 |
| Macarone, M | 1 |
| Fiamingo, P | 1 |
| Cappello, D | 1 |
| Gagliano, M | 1 |
| Di Mare, M | 1 |
| Vizcarra, D | 1 |
| Spataro, M | 1 |
| Giuffrida, G | 1 |
| Sorbello, M | 1 |
| Severino, V | 1 |
| Veroux, P | 1 |
| Skiest, DJ | 1 |
| Vazquez, JA | 1 |
| Anstead, GM | 1 |
| Graybill, JR | 1 |
| Reynes, J | 1 |
| Ward, D | 1 |
| Hare, R | 1 |
| Boparai, N | 1 |
| Isaacs, R | 1 |
| Force, RW | 1 |
| Nahata, MC | 1 |
| Prignet, JM | 1 |
| Galzin, M | 1 |
| Demarquay, JF | 1 |
| Raynard, B | 1 |
| Louvety, S | 1 |
| Künkel, D | 1 |
| Agresti, MG | 1 |
| de Bernardis, F | 1 |
| Mondello, F | 1 |
| Bellocco, R | 1 |
| Carosi, GP | 1 |
| Caputo, RM | 1 |
| Milazzo, F | 1 |
| Chiodo, F | 1 |
| Giannini, V | 1 |
| Minoli, L | 1 |
| Akova, M | 1 |
| Akalin, HE | 1 |
| Uzun, O | 1 |
| Hayran, M | 1 |
| Tekuzman, G | 1 |
| Kansu, E | 1 |
| Aslan, S | 1 |
| Telatar, H | 1 |
| Laine, L | 3 |
| Lesur, G | 1 |
| Paupard, T | 1 |
| Turner, L | 1 |
| Bergemer, AM | 1 |
| Parlier, H | 1 |
| Dupuy, P | 1 |
| Háber, J | 1 |
| Kolesková, E | 1 |
| Kostelková, A | 1 |
| Klener, P | 1 |
| Slavícek, A | 1 |
| Palecek, A | 1 |
| Másová, I | 1 |
| Sanguineti, A | 1 |
| Carmichael, JK | 1 |
| Campbell, K | 1 |
| Rabeneck, L | 1 |
| Cartledge, JD | 2 |
| Midgley, J | 2 |
| Gazzard, BG | 2 |
| Eichel, M | 1 |
| Just-Nübling, G | 1 |
| Helm, EB | 1 |
| Stille, W | 1 |
| Wildfeuer, A | 1 |
| Laufen, H | 1 |
| Yeates, RA | 1 |
| Zimmermann, T | 1 |
| Taylor, CB | 1 |
| Finlay, R | 1 |
| Richardson, C | 1 |
| Bunting, P | 1 |
| Welch, J | 1 |
| Wilcox, CM | 2 |
| Alexander, LN | 1 |
| Clark, WS | 1 |
| Thompson, SE | 1 |
| Barantsevich, EP | 1 |
| Antonov, VV | 1 |
| Nizamutdinova, AS | 1 |
| Darouiche, RO | 2 |
| Moskovitz, BL | 1 |
| Mallegol, I | 1 |
| Wu, J | 1 |
| Petrou, M | 1 |
| Shanson, D | 1 |
| Fortun Abete, J | 1 |
| Laing, RB | 1 |
| Brettle, RP | 1 |
| Leen, CL | 1 |
| Hood, SV | 1 |
| Hollis, S | 1 |
| Percy, M | 1 |
| Atkinson, G | 1 |
| Williams, K | 1 |
| Denning, DW | 1 |
| Gonzalez, CE | 1 |
| Piscitelli, S | 1 |
| Bacher, JD | 1 |
| Peter, J | 1 |
| Torres, R | 1 |
| Shetti, D | 1 |
| Katsov, V | 1 |
| Kligys, K | 1 |
| Lyman, CA | 2 |
| Schaufele, RL | 1 |
| Francesconi, A | 1 |
| Piscitelli, SC | 1 |
| Ally, R | 1 |
| Schürmann, D | 1 |
| Kreisel, W | 1 |
| Carosi, G | 1 |
| Aguirrebengoa, K | 1 |
| Dupont, B | 1 |
| Hodges, M | 1 |
| Troke, P | 1 |
| Romero, AJ | 1 |
| Barchiesi, F | 1 |
| Giacometti, A | 1 |
| Arzeni, D | 1 |
| Branchesi, P | 1 |
| Crescenzi, G | 1 |
| Ancarani, F | 1 |
| Scalise, G | 1 |
| Lavilla Uriol, P | 1 |
| Gil, A | 2 |
| Valencia, E | 2 |
| Pintado, V | 2 |
| López Dupla, M | 2 |
| Khamashta, M | 2 |
| García Puig, J | 2 |
| Ortiz Vázquez, J | 1 |
| Garber, GE | 1 |
| Lavilla, P | 1 |
| Ortiz-Vázquez, J | 1 |
| Lucatorto, FM | 1 |
| Franker, C | 1 |
| Hardy, WD | 1 |
| Chafey, S | 1 |
| Kitchen, VS | 1 |
| Savage, M | 1 |
| Harris, JR | 1 |
| Chave, JP | 1 |
| Francioli, P | 1 |
| Hirschel, B | 1 |
| Glauser, MP | 1 |
| Hendel, L | 1 |
| Svejgaard, E | 1 |
| Walsøe, I | 1 |
| Kieffer, M | 1 |
| Stenderup, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Comparative Trial of Micafungin Versus Fluconazole for the Treatment of Esophageal Candidiasis[NCT00666185] | Phase 3 | 523 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| An Open Multicenter Trial of Fluconazole Oral Suspension in the Treatment of Esophageal Candidiasis in Immunocompromised Patients[NCT00002339] | Phase 3 | 100 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fluconazole and Esophageal Diseases
| Article | Year |
|---|---|
[Diagnosis, treatment and prevention of infections caused by fungi in HIV-positive patients].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Aspergillosis; Cand | 1995 |
Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.
Topics: Antifungal Agents; Candidiasis, Oral; Drug Resistance, Microbial; Esophageal Diseases; Fluconazole; | 1998 |
Fluconazole: a new option in the treatment of Candida mucositis and esophageal candidiasis.
Topics: Candidiasis; Candidiasis, Oral; Esophageal Diseases; Fluconazole; HIV Infections; Humans; Mouth Muco | 1992 |
15 trials available for fluconazole and Esophageal Diseases
| Article | Year |
|---|---|
A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis; Double-Blind Method; Esophageal Disease | 2015 |
Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Candida; Candidiasis; Caspofungin; Cohort Studies; | 2002 |
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
Topics: Administration, Oral; Adult; Aged; Anidulafungin; Antifungal Agents; Candidiasis; Double-Blind Metho | 2004 |
A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis; Doub | 2004 |
A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candidiasis; Double-Blind Method; Echinocandins; Esophag | 2005 |
Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Candidiasis; Candidiasis, Oral; | 2007 |
Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis.
Topics: Administration, Oral; Adult; Candida albicans; Candidiasis; Chromatography, High Pressure Liquid; Cr | 1995 |
Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antigens, Fungal; Candida albicans; Candidiasis; Esoph | 1994 |
Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome.
Topics: Adult; Candida; Candidiasis, Oral; Esophageal Diseases; Female; Fluconazole; Humans; Male; Middle Ag | 1994 |
Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis; | 1995 |
Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms.
Topics: Adult; Antifungal Agents; Candidiasis; Cost-Benefit Analysis; Esophageal Diseases; Esophagitis; Esop | 1996 |
A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis.
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis; Double-Blind Method; Esophageal Disease | 1997 |
Assessment of therapeutic response of oropharyngeal and esophageal candidiasis in AIDS with use of a new clinical scoring system: studies with D0870.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis, Oral; Colon | 1999 |
A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candidiasis; Consumer Product Safety; Double-Blind Metho | 2001 |
[Secondary prevention of esophageal candidiasis with fluconazole in acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; Candidiasis; Esophageal Diseases; Female; Fluconazole; Fo | 1992 |
32 other studies available for fluconazole and Esophageal Diseases
| Article | Year |
|---|---|
Recidivant odynophagia secondary to persistent esophageal candidiasis in an immunocompetent patient: the importance of brush cytology.
Topics: Candidiasis; Deglutition Disorders; Esophageal Diseases; Esophagitis; Female; Fluconazole; Humans; M | 2022 |
Oesophageal intramural pseudodiverticulosis: a rare endoscopic finding.
Topics: Adult; Anti-Bacterial Agents; Antifungal Agents; Candidiasis; Deglutition Disorders; Endoscopy, Dige | 2019 |
Rectal Candidiasis Mimicking Ulcerative Colitis in an Immunocompetent Patient.
Topics: Aged; Candida; Candidiasis; Colitis, Ulcerative; Diagnosis, Differential; Endoscopy, Gastrointestina | 2019 |
Oesophageal tuberculosis with concomitant candidiasis: a rare cause of dysphagia.
Topics: Antifungal Agents; Antitubercular Agents; Candidiasis; Deglutition Disorders; Esophageal Diseases; F | 2019 |
Dysphagia: More Than Meets the Eye?
Topics: Aged; Antifungal Agents; Candida; Candidiasis; Deglutition Disorders; Diagnosis, Differential; Endos | 2018 |
A rapidly regressive esophageal squamous papilloma.
Topics: Anti-HIV Agents; Antifungal Agents; Candidiasis; Esophageal Diseases; Esophageal Neoplasms; Fluconaz | 2019 |
Is empiric therapy with fluconazole appropriate for esophageal candidiasis?
Topics: Adult; Candida albicans; Candida glabrata; Candidiasis; Drug Resistance, Fungal; Esophageal Diseases | 2014 |
Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida albicans; Candidemia; Child; | 2014 |
[Antifungal susceptibility for Candida albicans isolated from AIDS patients with oropharyngeal and esophageal candidiasis: experience with Etest].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida albicans; Candidia | 2003 |
Efficacy of PLD-118, a novel inhibitor of candida isoleucyl-tRNA synthetase, against experimental oropharyngeal and esophageal candidiasis caused by fluconazole-resistant C. albicans.
Topics: Animals; Antifungal Agents; Area Under Curve; Candida albicans; Candidiasis; Candidiasis, Oral; Cycl | 2004 |
Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice.
Topics: Animals; Antifungal Agents; Azepines; Bridged-Ring Compounds; Candida; Candida albicans; Candidiasis | 2005 |
Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients.
Topics: Adult; Aged; Antifungal Agents; Candidiasis; Candidiasis, Vulvovaginal; Caspofungin; Cyclosporine; E | 2006 |
[Esophageal candidiasis during interferon therapy for chronic viral hepatitis C].
Topics: Candidiasis; Esophageal Diseases; Female; Fluconazole; Hepatitis C; Hepatitis, Chronic; Humans; Inte | 1994 |
The natural history of esophageal candidiasis after successful treatment in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antifungal Agents; Candidiasis; Esophageal Diseases; Fluc | 1994 |
[Esophageal mycosis during treatment with omeprazole].
Topics: Esophageal Diseases; Fluconazole; Humans; Male; Middle Aged; Mycoses; Omeprazole; Stomach Ulcer | 1993 |
[Treatment of oropharyngeal and esophageal mycoses in immunodeficient patients with fluconazole (Diflucan, Pfizer)].
Topics: Adult; Aged; Esophageal Diseases; Female; Fluconazole; Humans; Immunocompromised Host; Male; Middle | 1993 |
Fluconazole-resistant Candida albicans after long-term suppressive therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Candida albicans; Candidiasis; Candidiasis, Oral; Drug | 1993 |
Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidosis.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis, Oral; Drug Resistanc | 1996 |
[Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candida albicans; Candidiasis; Ca | 1996 |
[A new pharmaceutical concept for the therapy of oropharyngeal and esophageal candidiasis with fluconazole].
Topics: Administration, Oral; Aged; Antifungal Agents; Candidiasis; Candidiasis, Oral; Cross-Over Studies; E | 1996 |
Rationalizing prescribing for oral and oesophageal candidiasis.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis; Candidiasis, Oral; Drug Costs | 1996 |
[Use of Diflucan in the treatment of chronic and recurrent candidosis with involvement of the esophagus].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candidiasis; Child; Chronic Disease; | 1996 |
Unresponsive HIV-related oro-oesophageal candidosis--an evaluation of two new in-vitro azole susceptibility tests.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis, Oral; Drug Resistanc | 1997 |
Clinical predictors of azole resistance, outcome and survival from oesophageal candidiasis in AIDS patients.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Body Weight; Candidiasis; CD4 Lymphocyte C | 1998 |
Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Topics: Animals; Candidiasis; Candidiasis, Oral; Child; Colony Count, Microbial; Disease Models, Animal; Dru | 2000 |
Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Topics: Amphotericin B; Anidulafungin; Animals; Antifungal Agents; Candidiasis; Candidiasis, Oral; Drug Resi | 2001 |
Fluconazole and ketoconazole in the treatment of oral and esophageal candidiasis in AIDS patients.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Candidiasis; Candidiasis, Oral; Esophageal Disea | 1992 |
[Treatment of esophageal candidiasis with fluconazole in acquired immunodeficiency syndrome. Comparative study of 2 therapeutic schemes].
Topics: Acquired Immunodeficiency Syndrome; Adult; Candidiasis; Drug Administration Schedule; Esophageal Dis | 1992 |
Treatment of refractory oral candidiasis with fluconazole. A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Candida albicans; Candidiasis, Oral; Clot | 1991 |
Candida albicans resistance in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Candidiasis, Oral; Drug Resistance, Microbial; Esophageal | 1991 |
Single-dose therapy for esophageal candidiasis with fluconazole.
Topics: Administration, Oral; Adult; Candidiasis; Esophageal Diseases; Female; Fluconazole; HIV Infections; | 1990 |
Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole.
Topics: Adult; Aged; Antifungal Agents; Candidiasis; Esophageal Diseases; Esophagoscopy; Female; Fluconazole | 1988 |